RS105004A - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method - Google Patents

Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Info

Publication number
RS105004A
RS105004A YUP-1050/04A YUP105004A RS105004A RS 105004 A RS105004 A RS 105004A YU P105004 A YUP105004 A YU P105004A RS 105004 A RS105004 A RS 105004A
Authority
RS
Serbia
Prior art keywords
substance
subcutaneous dose
fsh
amount equivalent
dosage unit
Prior art date
Application number
YUP-1050/04A
Other languages
English (en)
Inventor
Evert Johannes Bunschoten
Bennink Herman Coelingh
Original Assignee
Ares Trading S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A., filed Critical Ares Trading S.A.,
Publication of RS105004A publication Critical patent/RS105004A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Jedan aspekt ovog pronalaska se odnosi na metodu kontrolisane hiperstimulacije jajnika kod ženki sisara, gde ova metoda obuhvata paralelno davanje supstance koja ima aktivnost folikulostimulirajućeg hormona (FSH) datoj ženki u količini koja je delotvorna da stimuliše multipli folikularni razvoj; antagonist hormona koji oslobadja gonadotropin (GnRH) u količini koja je ekvivalentna dnevnoj supkutanoj dozi od najmanje 0,5 mg ganireliksa da se spreči prerana plima LH; i supstance LH u količini koja je dovoljna da se spreče ili suprimiraju simptomi deficijencije luteinizirajuceg hormona do čega dolazi zbog davanja antagonista GnRH; posle čega sledi davanje supstance za indukciju mejoze i luteinizacije (supstanca ML) u količini koja je dovoljna da stimuliše ponovni početak mejoze i luteinizacije, naznačeno time da se supstanca LH ne dobija iz urina žena. Drugi aspekt ovog pronalaska odnosi se na farmaceutski komplet za korišćenje u metodi kontrolisane ovarijalne hipestimulacije, gde ovaj komplet obuhvata: najmanje jednu parenteralnu ili oralnu jedinicu doziranja koja sadrži jednu ili više supstanci FSH u količini koja je ekvivalentna supkutanoj dozi od 50-1500 IU FSH, najmanje jednoj parenteralnoj jedinici doziranja koja sadrži jedan ili više antagonista GnRH u količini koja je ekvivalentna supkutanoj dozi od 0,5-25 mg ganireliksa; najmanje jednu parenteralnu jedinicu doziranja koja sadrži jednu ili više supstanci LH u kolicini koja je ekvivalentna supkutanoj dozi od 50-3000 IU rekombinantnog LH naznaceno time da se supstanca LHG ne dobija iz urina žena.
YUP-1050/04A 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method RS105004A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077221 2002-06-07
PCT/NL2003/000370 WO2003103770A2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Publications (1)

Publication Number Publication Date
RS105004A true RS105004A (en) 2007-02-05

Family

ID=29724462

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-1050/04A RS105004A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Country Status (21)

Country Link
US (1) US7815912B2 (sr)
EP (1) EP1511537B1 (sr)
JP (1) JP2005530818A (sr)
KR (1) KR20050058285A (sr)
CN (1) CN1684737A (sr)
AU (1) AU2003274929B2 (sr)
BR (1) BR0305033A (sr)
CA (1) CA2488719A1 (sr)
EA (1) EA009371B1 (sr)
ES (1) ES2399962T3 (sr)
IL (1) IL165522A0 (sr)
IS (1) IS7586A (sr)
ME (1) MEP39308A (sr)
MX (1) MXPA04012246A (sr)
NO (1) NO20045304L (sr)
NZ (1) NZ536984A (sr)
PL (1) PL373991A1 (sr)
RS (1) RS105004A (sr)
UA (1) UA81251C2 (sr)
WO (1) WO2003103770A2 (sr)
ZA (1) ZA200409857B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114412B1 (en) * 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US9353172B2 (en) 2011-07-18 2016-05-31 Arts Biologics A/S Long acting biologically active luteinizing hormone (LH) compound
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US9282995B2 (en) * 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US9216037B2 (en) 2013-06-21 2015-12-22 Previvo Genetics, Llc Uterine lavage for embryo retrieval
SG11201900461UA (en) 2016-07-21 2019-02-27 ObsEva SA Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
JP2022546716A (ja) 2019-09-03 2022-11-07 オブセヴァ エス．エー． 胚着床を促進し、流産を防止するためのオキシトシンアンタゴニスト投与レジメン
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A3 (en) * 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
CN1199642A (zh) * 1997-05-16 1998-11-25 Asta药物股份公司 治疗不育症的lhrh－拮抗剂
US6653286B1 (en) 1997-06-20 2003-11-25 Akzo Nobel Nv Gonadotropin releasing hormone antagonist
HU228736B1 (en) * 1998-04-23 2013-05-28 Zentaris Ivf Gmbh Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders
JP2002537349A (ja) * 1999-02-24 2002-11-05 ノボ ノルディスク アクティーゼルスカブ 不妊症の治療
US20030092628A1 (en) * 1999-06-23 2003-05-15 De Greef Henrik Johan Matthieu Maria Gonadotropin releasing hormone antagonist
AU6263800A (en) 1999-06-23 2001-01-31 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
DK1434600T3 (da) * 2001-09-12 2009-05-25 Serono Lab Anvendelse af LH i kontrolleret ovarie-hyperstimulation
DE60223284T2 (de) 2001-12-21 2008-07-31 Pantarhei Bioscience B.V. Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutischen kit zur verwendung in diesem verfahren

Also Published As

Publication number Publication date
IS7586A (is) 2004-12-03
NO20045304L (no) 2005-02-07
MEP39308A (en) 2011-02-10
EP1511537A2 (en) 2005-03-09
AU2003274929A1 (en) 2003-12-22
CN1684737A (zh) 2005-10-19
EA200401619A1 (ru) 2005-06-30
ES2399962T3 (es) 2013-04-04
PL373991A1 (en) 2005-09-19
UA81251C2 (en) 2007-12-25
US7815912B2 (en) 2010-10-19
AU2003274929B2 (en) 2008-04-10
ZA200409857B (en) 2006-02-22
CA2488719A1 (en) 2003-12-18
US20050235374A1 (en) 2005-10-20
WO2003103770A2 (en) 2003-12-18
KR20050058285A (ko) 2005-06-16
IL165522A0 (en) 2006-01-15
EA009371B1 (ru) 2007-12-28
EP1511537B1 (en) 2012-11-21
NZ536984A (en) 2008-01-31
BR0305033A (pt) 2004-11-09
WO2003103770A3 (en) 2004-04-22
MXPA04012246A (es) 2005-04-08
JP2005530818A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
Haynes et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats
US4994446A (en) Drug system
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
Abbud et al. Differences in the Luteinizing Hormone and Prolactin Responses to Multiple Injections of Kainate, as Compared to iV-Methyl-D, L-Aspartate, in Cycling Rats
US20150190404A1 (en) Treating seizures using ice inhibitors
Sahu et al. Dynamic changes in neuropeptide Y concentrations in the median eminence in association with preovulatory luteinizing hormone release in the rat
RS105004A (en) Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
AU2002310788B2 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
US20110195898A1 (en) Treatment of alzheimer's disease and mild cognitive impairment using gnrh-i analogs and one or more of acetylcholinesterase inhibitors and nmda receptor antagonists
Gay The hypothalamus: physiology and clinical use of releasing factors
AU2002358346A1 (en) Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
DE60315490T2 (de) Therapeutische behandlung
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
US6437093B1 (en) Methods of treatment comprising administration of Substance P
MXPA03009447A (es) Inhibidor de aromatasa de dosis unica para tratamiento de infertilidad.
US20200281957A1 (en) Use of scutellarin in a medicament and a modulator for preventing or treating diseases, medicament, and modulator
CA2472309A1 (en) Multiple dose aromatase inhibitor for treating infertility
Formisano et al. Nimodipine in migraine: clinical efficacy and endocrinological effects
Birkhaeuser Ovulation Induction by Pulsatile Administration of GnRH: State of the Art
KR101190529B1 (ko) Ｉｃｅ 억제제를 사용하는 발작의 치료
KR20010076961A (ko) 성기능장애 예방 및 치료용 약제
Tadir et al. Comparison of Pituitary Response to Regular GnRH, Analogue (D–TRP6) and Placebo
US7834040B2 (en) Isoxazolic derivative to relieve neuropathic pain
Mettler et al. Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET)
Bercu et al. The Effect of Growth Hormone Secretagogues on the Release of Growth Hormone-Releasing Hormone, Somatostatin, Vasopressin, and Corticotrophin-Releasing Hormone frorn the Rat Hypothalamus In Vitro